IVVD
Invivyd, Inc. Common Stock
stockNASDAQ
adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.62 | 2026-10-16 | -2.08% | 3.328 |
| 1M | 0.92 | 2026-09-23 | -34.38% | 4.053 |
| 3M | 0.61 | 2026-07-23 | -0.57% | 3.670 |
| 6M | 1.51 | 2026-04-23 | -59.89% | 2.166 |
| 1Y | 1.94 | 2025-10-23 | -68.78% | 2.012 |
| 2Y | 0.99 | 2024-10-23 | -38.71% | — |
| 5Y | 4.38 | 2022-09-14 | -86.17% | 1.388 |
Invivyd, Inc. Common Stock (NASDAQ:IVVD) stock price today is $0.61, and today's volume is 2,524,948. IVVD is down 0.721% today. The 30 day average volume is 6.62M. IVVD market cap is $178.54M with 294.76M shares outstanding.